Abstract: A continuous flow system for the synthesis of nanoparticles includes a feeding unit connected to the first reactor a flow path, at least one first reactor unit possessing a heatable reactor-zone, a second reactor unit which follows the first reactor in the same cascade; a mixing unit and a second feeding unit between the reactor units, and feeding pumps connected to a raw material source and/or a control unit which is capable of controlling at least one pressure controller and/or controlling the temperature of at least one heatable reactor-zone; each heatable reactor-zone is followed by a cooling unit in the cascade. In addition, a process for the synthesis of nanoparticles, preferably metal-containing nanoparticles, and nanoparticles of biologically active organic molecules wherein the process is accomplished using the system.

Abstract: The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.

Abstract: The present invention is directed to nanostructured Ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Ezetimibe according to the invention have an average particle size of less than about 400 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance compared to the marketed drug. Ezetimibe is an anti-hyperlipidemic medication that is used to lower cholesterol levels. It acts by decreasing cholesterol absorption in the intestine.

Abstract: The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them according to the invention have an average particle size of less than about 500 nm. Sildenafil citrate is inhibiting cGMP specific phosphodiesterase type 5 (PDEV), an enzyme that regulates blood flow in the penis. The compositions of the invention are useful in the treatment of male or female sexual dysfunction and pulmonary arterial hypertension (PAH).

Abstract: The subject of the invention is the (50) continuous flow system for the synthesis of nanoparticles which consist of the (1a) feeding unit connected to the flow path, at least one (2) first reactor unit possessing the (13) heatable reactor-zone, the (3) second reactor unit which follows (2) in the same cascade; the (5) mixing unit and the (1b) second feeding unit between (2) and (3) reactor units, the (9) and (10) feeding pumps connected to the raw material source and/or (22) control unit which is capable of controlling at least one (18) pressure controller and/or controlling the temperature of at least one (13) heatable reactor-zone; each (13) heatable reactor-zone is followed by (14) cooling unit in the cascade. In addition, the subject of this invention is a process for the synthesis of nanoparticles, preferably metal-containing nanoparticles, and nanoparticles of biologically active organic molecules wherein the process is accomplished in the device according to FIG. 1.